Atinvicitinib

Atinvicitinib
Clinical data
ATCvet code
Identifiers
  • 1-[(3R,4S)-4-cyanooxan-3-yl]-3-[(2-fluoro-6-methoxypyridin-4-yl)amino]pyrazole-4-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC16H17FN6O3
Molar mass360.349 g·mol−1
3D model (JSmol)
  • COc1cc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)cc(F)n1
  • InChI=1S/C16H17FN6O3/c1-25-14-5-10(4-13(17)21-14)20-16-11(15(19)24)7-23(22-16)12-8-26-3-2-9(12)6-18/h4-5,7,9,12H,2-3,8H2,1H3,(H2,19,24)(H,20,21,22)/t9-,12+/m1/s1
  • Key:PRQMBGDYXWVEHE-SKDRFNHKSA-N

Atinvicitinib is a veterinary medicinal product under investigation for the treatment of atopic dermatitis in dogs.[1] Atinvicitinib is a selective Janus kinase (JAK) inhibitor, highly selective for Janus kinase 1 (JAK1). It inhibits the function of a variety of cytokines involved in itch and inflammation, as well as cytokines involved in allergy, that are dependent on JAK1 enzyme activity.[1] Reduction of allergy mediated inflammation, which is dependent on JAK1 enzyme activity, leads to a reduction of inflammation associated white blood cell counts (within the reference range).[1]

Society and culture

In June 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Numelvi, tablets, intended for dogs.[1] The applicant for this veterinary medicinal product is Intervet International B.V.[1]

Names

Atinvicitinib is the international nonproprietary name.[2]

References

  1. ^ a b c d e "Numelvi EPAR". European Medicines Agency (EMA). 11 June 2025. Retrieved 15 June 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ^ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.


Stub icon

This dermatologic drug article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.